Mirum Pharmaceuticals, Inc. Increase (Decrease) in Accounts Receivable
Mirum Pharmaceuticals, Inc. (MIRM) reported Increase (Decrease) in Accounts Receivable of $26.63 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $13.74M, a 51.57% increase year-over-year.
- Mirum Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $12.89M, a 23.45% decline year-over-year.
- Mirum Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $19.01M, a 74.96% increase year-over-year.
- Mirum Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $3.15M, a 61.16% decline year-over-year.
- Mirum Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2025 was $48.05M, a 320.58% increase from fiscal 2024.
- Mirum Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $11.43M, a 74.02% decline from fiscal 2023.
- Mirum Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $43.97M, a 112.16% increase from fiscal 2022.
- Mirum Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2022 was $20.73M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $26.63M 10-Q · filed 2026-08-05 | $45.64M derived: sum of 3 quarters · filed 2026-08-05 | $48.78M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $12.89M 10-Q · filed 2026-05-06 | $31.89M derived: sum of 2 quarters · filed 2026-05-06 | $35.04M derived: sum of 3 quarters · filed 2026-05-06 | $44.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $19.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $22.15M derived: sum of 2 quarters · filed 2026-02-25 | $31.22M derived: sum of 3 quarters · filed 2026-08-05 | $48.05M 10-K · filed 2026-02-25 |
| 2025-09-30 | $3.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $12.21M derived: sum of 2 quarters · filed 2026-08-05 | $29.05M 10-Q · filed 2025-11-04 | $39.91M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $9.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $25.90M 10-Q · filed 2026-08-05 | $36.77M derived: sum of 3 quarters · filed 2026-08-05 | $44.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $16.83M 10-Q · filed 2026-05-06 | $27.70M derived: sum of 2 quarters · filed 2026-05-06 | $35.80M derived: sum of 3 quarters · filed 2026-05-06 | $41.23M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $10.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $18.96M derived: sum of 2 quarters · filed 2026-02-25 | $24.39M derived: sum of 3 quarters · filed 2026-02-25 | $11.43M 10-K · filed 2026-02-25 |
| 2024-09-30 | $8.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $13.53M derived: sum of 2 quarters · filed 2025-11-04 | $562.00K 10-Q · filed 2025-11-04 | $20.70M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $5.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$7.54M 10-Q · filed 2025-08-06 | $12.60M derived: sum of 3 quarters · filed 2026-02-25 | $25.10M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$12.97M 10-Q · filed 2025-05-07 | $7.17M derived: sum of 2 quarters · filed 2026-02-25 | $19.67M derived: sum of 3 quarters · filed 2026-02-25 | $30.34M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $20.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $32.64M derived: sum of 2 quarters · filed 2026-02-25 | $43.31M derived: sum of 3 quarters · filed 2026-02-25 | $43.97M 10-K · filed 2026-02-25 |
| 2023-09-30 | $12.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $23.17M derived: sum of 2 quarters · filed 2024-11-12 | $23.84M 10-Q · filed 2024-11-12 | $31.50M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $10.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $11.33M 10-Q · filed 2024-08-07 | $18.99M derived: sum of 3 quarters · filed 2025-02-26 | $21.34M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $667.00K 10-Q · filed 2024-05-08 | $8.32M derived: sum of 2 quarters · filed 2025-02-26 | $10.67M derived: sum of 3 quarters · filed 2025-02-26 | $16.79M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $7.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $10.00M derived: sum of 2 quarters · filed 2025-02-26 | $16.12M derived: sum of 3 quarters · filed 2025-02-26 | $20.73M 10-K · filed 2025-02-26 |
| 2022-09-30 | $2.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $8.46M derived: sum of 2 quarters · filed 2023-11-02 | $13.07M 10-Q · filed 2023-11-02 | $13.07M derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-06-30 | $6.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $10.72M 10-Q · filed 2023-08-07 | $10.72M derived: sum of 3 quarters · filed 2024-03-15 | $10.72M derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-03-31 | $4.61M 10-Q · filed 2023-05-04 | $4.61M derived: sum of 2 quarters · filed 2024-03-15 | $4.61M derived: sum of 3 quarters · filed 2024-03-15 | $4.61M derived: sum of 4 quarters · filed 2024-03-15 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $0.00 derived: sum of 2 quarters · filed 2024-03-15 | $0.00 derived: sum of 3 quarters · filed 2024-03-15 | $0.00 10-K · filed 2024-03-15 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |